Stock Yards Bancorp Named to Bank Director’s Ranking Banking Top 25, Ranks 17th Overall

Stock Yards Bancorp (SYBT) reported Q3 EPS of $1.40, beating estimates by $0.07, with revenue at $120.24M, exceeding expectations. The stock is down 7.87% over 3 months but up 18.04% year-over-year. InvestingPro rates its financial health as 'good performance'.

Stock Yards Bancorp reported Q3 2026 net income of $43.5M, up from $40.1M in Q2 and $36.2M a year earlier. Revenue rose to $120.3M, with net interest income up 20% YoY. The company completed Field & Main acquisition integration and opened a new branch. Management aims to stay below $10B asset threshold until 2027, according to the company.

Stock Yards Bancorp, Inc. (SYBT) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 Stock Yards Bancorp Reports Record Third Quarter Earnings of $43.5 Million or $1.40 per Diluted Share Third Quarter Highlighted by Net Interest Margin Expansion and Record Non-Interest Income LOUISVILLE, Ky., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Stock Yards Bancorp, Inc

Stock Yards Bancorp, Inc. (SYBT) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 Stock Yards Bancorp Reports Record Second Quarter Earnings of $40.1 Million or $1.31 Per Diluted Share Second Quarter Highlighted by the Completed Acquisition of Field & Main Bancorp Along with Margin Expansion and Record Non-Interest Income LOUISVILLE, Ky., July 29,

Regional bank stocks rose in an afternoon rally as the Russell 2000 gained 1.4%, outperforming the S&P 500 and Nasdaq. The article links the move to improving net interest margins, citing Q1 results and a “higher-for-longer” Fed rate stance at 3.75%. Stock Yards Bank (SYBT) and Coastal Financial (CCB) each rose 3.3%.

Geron Corporation (GERN) shares fell over 20% after the company halted a late-stage trial for its cancer drug Rytelo due to efficacy concerns, according to the company.